Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.18 USD | +1.55% | -11.66% | -35.13% |
01:24pm | Guggenheim Upgrades Amicus Therapeutics to Buy From Neutral With $13 Price Target | MT |
10/05 | UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.13% | 267.76Cr | |
+29.48% | 4.82TCr | |
-0.59% | 4.17TCr | |
+43.06% | 4.1TCr | |
-5.31% | 2.88TCr | |
+10.13% | 2.56TCr | |
-22.57% | 1.9TCr | |
+8.93% | 1.29TCr | |
+28.69% | 1.2TCr | |
-2.30% | 1.18TCr |
- Stock Market
- Equities
- FOLD Stock
- News Amicus Therapeutics, Inc.
- Amicus Therapeutics Insider Sold Shares Worth $449,545, According to a Recent SEC Filing